Below is a listing of the latest workers' compensation industry news and alerts. Our goal is to provide you with timely and relevant information. Visit the Industry News & Alerts Archive to view past items by date.
New dosing and a recommendation to avoid driving the day after Ambien CR use
Opana ER Extended-Release Tablets was not withdrawn for safety or effectiveness
Nutraceutical company XYMOGEN in Orlando, Fla., is recalling artriphen
Practices at The Compounding Shop in FL raise concerns about sterility assurance
Versions of Botox that are not approved by the FDA are being sold to medical practices.
Nora Apothecary & Alternative Therapies recall of all sterile drug products
FDA announces nationwide recall by Balanced Solutions Compounding Pharmacy
Agency will not approve generics to original OxyContin
Voluntary Nationwide Recall of All Lots of All Sterile Products
Results of compounding pharmacies inspections
Campaign to raise awareness of the dangers of medicines from fake online pharmacies
The Drug Enforcement Administration has scheduled another Prescription Drug Take-Back Day April 27
Recall of All Sterile Compounded Products Dispensed Since January 2013
Recall Compounded Products Due To Potential Mold Contamination
Clinical Specialties is voluntarily recalling all lots of all sterile products
FDA offers some tip-offs to help you identify rip-offs
Possible Increased Risk of Pancreatitis and Pre-Cancerous Pancreas Findings
Azithromycin can cause abnormal changes in the electrical activity of the heart
Recalling all lots of Tablets Due to Undeclared Drug Ingredients
Governor’s budget provides resources for pharmacy inspections and oversight
FDA warns about serious blood disorder resulting from misuse of Opana ER
FDA requires lower recommended doses for drugs containing zolpidem
Pays to Resolve Kickback Allegations in Connection with Promotion of Its Drugs
Recall Impacts Three Lots of Hydrocodone Bitartrate and Acetaminophen Tablets
Pradaxa should not be used to prevent stroke or blood clots in patients
Reumofan Plus is being relabeled and sold under the name “WOW"
Serious skin reactions after combination treatment
FDA is informing the public about the results of a large, combined analysis
Recall of 101 Lots of Hydrocodone Bitartrate and Acetaminophen Tablets
Ranbaxy Pharmaceuticals Inc. is conducting a recall for Atorvastatin
Ameridose announced a voluntary recall of any unexpired products in circulation
Emergency Suspension Order (ESO) of Rejuvi Pharmaceuticals, Inc.
The FDA approved Fycompa tablets to treat partial onset seizures in patients with epilepsy
NextWave Pharmaceuticals Receives FDA Approval of Quillivant XR™
FDA provides NECC Customer List
The FDA recently found cases of blood disorders occurred in abusers of Opana ER
Meningitis Outbreak: Additional Patient Notification Advised
The FDA took action this week against Internet pharmacies
U.S. Files Criminal Charges in Connection with Misbranded Drug Shipment
Investigation of Aspergillus meningitis among patients who received medication
Subpotent; some patches may not contain fentanyl gel
Label Mix-Up: Bottles labeled as Naproxen Tablets USP, 500 mg, 100-count may contain 90-count Pravastatin Sodium Tablets, 40
Sticker label applied by Dispensing Solutions Inc. incorrectly indicates product name
Pharmaceutical manufacturer may have distributed foreign tablets
RB confirms the company is discontinuing Suboxone Tablets in the US
The Drug Enforcement Administration (DEA) has scheduled another National Prescription Drug Take-Back Day
Tablets may contain higher than indicated amounts of the ingredients.
FDA notified healthcare profesionals about increased risk with Mirapex
Products applied to the skin have been reported to cause rare cases of skin injuries.
Tablets, exceed the weight specification and could be super-potent
Endo Pharmaceuticals Announces Reformulated Version of OPANA® ER with INTAC® Technology Designed to be Crush-Resistant Accounts for more than 90 Percent of OPANA ER Total Prescription Volume
Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received final approval from the United States Food and Drug Administration (FDA)
FDA Approves NUCYNTA® ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
The FDA issued a new warning to consumers about the potential health risks of two products marketed as natural dietary supplements.
The U.S. Food and Drug Administration today approved the first generic version of Actos tablets.
The FDA has approved label changes to a number of opioids to reflect the new REMS requirements.
Tizanidine Recall: Label Mix-Up; Some bottles of Tizanidine 4mg Tablets, had the incorrect manufacturer (Actavis) printed on the label.
The U.S. Food and Drug Administration today approved Tudorza Pressair for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
FDA approved a risk evaluation and mitigation strategy for extended-release and long-acting opioid medications.
Almost one-third of prescription painkiller overdose deaths involve methadone. Six times as many people died of methadone overdoses in 2009 than a decade before. Learn the facts and what you can do to address this problem
First generic pregabalin products approved.
The U.S. Food and Drug Administration today issued a Federal Register notice instructing companies to stop manufacturing and distributing certain unapproved drugs that contain oxycodone.
The FDA issued draft guidance to manufacturers of OTC acetaminophen products, providing alternative language to the liver warning section of the product’s labeling.
Important changes are coming to Vicodin
Undeclared Drug Ingredient
Tablets purchased on the Internet contain wrong active ingredients
Prescriptions Distributed by Franck’s Pharmacy From November 21, 2011 to May 21, 2012
FDA is reviewing the results from a New England Journal of Medicine study reporting a small increase in cardiovascular deaths, in persons treated with a 5-day course of azithromycin
FDA approved generic versions of the blood thinning drug Plavix (clopidogrel bisulfate), which helps reduce the risk of heart attack and stroke
New Warning and Contraindication for blood pressure medicines containing aliskiren
FDA Reminds the Public about the Potential for Life-Threatening Harm from Accidental Exposure to Fentanyl Transdermal Systems (“Patches”)
related to a potential risk of abnormal heart rhythms with high doses
Changes were made to the labels to provide the public with more information for the safe and effective use of statins.
This temporary shortage is not related to the efficacy or safety of Voltaren Gel.
Novartis Consumer Health Over-The-Counter Products: Recall - Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
FDA advises of potential safety risk associated with certain opiate products manufactured for Endo Pharmaceuticals by Novartis Consumer Health.
for transmucosal immediate-release fentanyl (TIRF) medicines
Review update of Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events
(atorvastatin calcium tablets)
Watson Pharmaceuticals Inc. announced FDA approval for its Abbreviated New Drug Application for morphine sulfate ER capsules USP
FDA warns that that the cholesterol-lowering medicine Trilipix (fenofibric acid) may not lower a patient's risk of having a heart attack or stroke.
NIH announces results from first large scale study on treatment of prescription opioid addiction
Kill more Americans than heroin and cocaine combined
Read the FDA Warning Letter and Notice of Violation Sent to Pfizer regarding Chantix®, Caduet® and Norvasc®
Serious allergic reactions
Abnormal Heart Rhythms Associated With High Doses
(tapentadol extended-release tablets) receives FDA approval for the management of moderate to severe chronic pain
To treat specific form of urinary incontinence
Serious CNS reactions possible when linezolid (Zyvox®) is given to patients taking certain psychiatric medications
Mcneil Consumer Healthcare Announces Plans For New Dosing Instructions For Tylenol® Products
to treat chronic obstructive pulmonary disease
Potiga (ezogabine) tablets approved by FDA for use as add-on medication to treat seizures associated with epilepsy
Increased Risk of Death or Serious Cardiovascular Events
Potential Increased Risk of Esophageal Cancer
First Fentanyl Nasal Spray - for the management of breakthrough pain in cancer patients
to prevent tetanus, diphtheria, and pertussis in older people
to reduce risk of blood clots after hip, knee replacements
(USP 50mg, 325mg, 40mg) and Hydrocodone Bitartrate and Acetaminophen Tablets (USP 7.5mg, 500mg): Bottle Mislabeled
Some Bottles Contain Different Strength Tablets
Recall - Uncharacteristic Odor
Oxycodone HCL, USP
REMS - Risk of Thyroid C-cell Tumors, Acute Pancreatitis
Label Change - Increased Risk of Prostate Cancer
Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-containing Medicines including Avandia, Avandamet and Avandaryl
The U.S. Food and Drug Administration today approved Tradjenta (linagliptin) tablets
FDA approves Horizant to treat restless legs syndrome
Improvements implement FSMA requirement
McNeil Consumer Healthcare announces voluntary recall of certain OTC products
Unapproved Product May Contain Dangerously High Levels of Vitamins A and D
Voluntary Nationwide Recall Due to Possible Mislabeling
King Pharmaceuticals Inc. has recalled Embeda® Extended Release Capsules CII
Maternal Treatment with Opioid Analgesics and Risk for Birth Defects
FDA approves Edarbi to treat high blood pressure
Amantadine, Amlodipine, Androxy, Baclofen, Bethanechol, Jantoven® and Oxybutynin
Medtronic SynchroMed II and SynchroMed EL Implantable Infusion Pump and Refill Kits: Class 1 Recall
Product is not FDA-approved
Covidien received approval of its Abbreviated New Drug Application (ANDA) for FTS patch
REMS - Risk of Cardiovascular Events
Once-Daily Tablets for Treatment of Post-Herpetic Neuralgia
FDA approved Viibryd tablets (vilazodone hydrochloride) to treat major depressive disorder in adults
Bristol-Myers Squibb and partner sanofi-aventis are voluntarily withdrawing certain lots of AVALIDE®
Certain lots of TYLENOL® 8 Hour, TYLENOL® Arthritis Pain, TYLENOL® Cold, TYLENOL® Allergy, TYLENOL® Sinus, BENADRYL®, SINUTAB® Sinus, SUDAFED PE® and ROLAIDS®
Severe liver injury associated with the use of dronedarone
Products to be Limited to 325 mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver Failure
100 mg per 5 mL (20 mg/mL): Medication Use Error - Reports of Accidental Overdose
The FDA approved Abstral (fentanyl) transmucosal tablets to manage breakthrough pain for adults with cancer.
Mislabeled Unit Dose Vials; voluntary recall in 25, 30, and 60 unit dose vials
Pfizer recalled specific bottles of LIPITOR (40 mg only)
Potential for Accidental Ingestion by Children
McNeil recalls all lots of Rolaids® extra strength softchews, extra strength plus gas softchews, and multi-symptom plus anti-gas softchews
Refenesen Expectorant;Select Brand Mucus Relief Expectorant; QC Medifin Expectorant;Leader Cough Tabs Expectorant
View recent recalls from McNeil Consumer Healthcare
Xanodyne Pharmaceuticals Inc. has withdrawn the prescription pain medication propoxyphene from the US market at the request of the FDA.
Safety update for osteoporosis drugs, bisphosphonates and atypical fractures
The FDA warns that Lamictal can cause aseptic meningitis.
Miracle Mineral Solution (MMS): Product as consumed produces a potent bleach
21 lots of over-the-counter medicines sold in US, Fiji, Guatemala, Dominican Republic, Puerto Rico, Trinidad & Tobago, and Jamaica are recalled.
Serious side effects reported when used to treat or prevent night time leg cramps
The U.S. Food and Drug Administration approved the first generic version of Effexor XR capsules (venlafaxine hydrochloride) to treat major depressive disorder.
P&G Voluntarily Recalls 4 Hour Decongestant Nasal Spray in the United States
FDA Drug Safety Communication: Ongoing safety review of Benicar and cardiovascular events
Blacksmith Brands Announces Nationwide Voluntary Recall Of Four PediaCare Children's Products
Completed safety review of Xenical/Alli (orlistat) and severe liver injury.
Goal is to expand online distribution of Agency’s consumer health information.
The FDA and the NIH launched a new Web site that, when fully developed, will provide a mechanism for the reporting of pre- and post-market safety data to the federal government.
Ortho-McNeil-Janssen and FDA notified healthcare professionals of changes to the Warnings section of the prescribing information for tramadol.
Proton Pump Inhibitors Class Labeling Change including Nexium, Dexilant, Prilosec, Zegerid, Prevacid, Protonix, Aciphex, Vimovo, Prilosec OTC, Zegerid OTC, and Prevacid 24HR
Change to Dexilant is part of FDA effort to prevent medication errors.
McNeil Consumer Healthcare Announces Voluntary Recall of Certain OTC Infants’ and Children’s Products
The FDA provides answers to questions about a new approved formulation of the controlled-release drug OxyContin.
The FDA approved a new formulation of the controlled-release drug OxyContin designed to help discourage abuse.
FDA warned company about making medical claims for bee-derived products.
A listing of recent new and generic drugs approved by the FDA.
Maalox product maker agrees to name change to avoid confusion.
FDA Approves Morphine Sulfate Oral Solution for Relief of Acute and Chronic Pain. Approval is part of Agency’s unapproved drugs initiative.
Alli 60 mg capsules (120 count refill kit): Counterfeit Product
Tylenol Arthritis Pain Caplet, 100 count bottles: Recall of all lots
McNeil Consumer Healthcare Announces Voluntary Recall of Certain Over-The-Counter (OTC) Products in the Americas, UAE, and Fiji
News | Press Releases | Press Release Archive | HES in the News | Events
Read present and past Healthesystems Press Releases :: more
Read articles in which Healthesystems is mentioned, quoted or used as an expert source :: more
View a collection of industry news items and industry alerts :: more
Find out which events Healthesystems will be attending and sponsoring :: more